recode-therapeutics
(3)
Shehnaaz Suliman built a career by changing the scale of the problem
From Cape Flats protests to Oxford, Wall Street and the biotech boardroom, Suliman kept asking one question: how can one decision reach more people?
Angèle Maki
Angèle Maki, PhD, is a biopharmaceutical business development executive with more than 20 years of deal-making across emerging biotechs and global pharma. In December 2025 she became the first Chief Business Officer of Ability Biotherapeutics, a Montreal-based company building logic-gated antibodies with its generative-AI platform AbiLeap. A Stanford-trained biological chemist who started at the University of Winnipeg, she has held senior roles at Medarex, Bristol Myers Squibb, Genentech, 23andMe, Merck, Eli Lilly, ReCode Therapeutics and Callio Therapeutics, and chairs the non-profit Canadian Entrepreneurs in Life Sciences.
David Lockhart
David J. Lockhart, Ph.D. is President and Chief Scientific Officer of ReCode Therapeutics, a clinical-stage biotech pioneering nonviral lipid nanoparticle (LNP) delivery of mRNA and gene-editing payloads to the lungs for genetic respiratory diseases including cystic fibrosis and primary ciliary dyskinesia. With more than 25 years in drug discovery and genomics — from co-founding Ambit Biosciences to leading science at Amicus Therapeutics — Lockhart brings rare-disease chops and deep genomics expertise to ReCode's SORT LNP platform, which has raised $345M and dosed its first patients in a Phase 1 PCD trial.